3260-94-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5,7-Difluoro-benzofuran-3-one is used as a building block for the synthesis of various pharmaceuticals and agrochemicals due to its unique structure and reactivity. Its incorporation into these compounds can enhance their efficacy and selectivity, making it a valuable component in the development of new drugs and pesticides.
Used in Drug Discovery and Development:
5,7-Difluoro-benzofuran-3-one is utilized as a key intermediate in the field of drug discovery and development. Its versatile reactivity allows for the creation of diverse chemical entities with potential therapeutic applications. Its physical and chemical properties make it an important compound for exploring novel treatments and advancing pharmaceutical research.
Used in Anti-Cancer Research:
5,7-Difluoro-benzofuran-3-one has been studied for its potential as an anti-cancer agent. Its unique structure may contribute to the modulation of cellular processes involved in cancer progression, making it a promising candidate for further research into cancer therapeutics. The exploration of its anti-cancer properties could lead to the development of new treatments for various types of cancer.

InChI:InChI=1/C8H5BrO2/c9-6-3-1-2-5-7(10)4-11-8(5)6/h1-3H,4H2

Upstream product

• 960063-96-1 C₁₀H₇ClO₃ 
• 52159-67-8 methyl 3-chloro-2-hydroxybenzoate 

Relevant academic research and scientific papers

Flavone inspired discovery of benzylidenebenzofuran-3(2H)-ones (aurones) as potent inhibitors of human protein kinase CK2

In this work, we describe the design, synthesis and SAR studies of 2-benzylidenebenzofuran-3-ones (aurones), a new family of potent inhibitors of CK2. A series of aurones have been synthesized. These compounds are structurally related to the synthetic flavones and showed nanomolar activities towards CK2. Biochemical tests revealed that 20 newly synthesized compounds inhibited CK2 with IC50 values in the nanomolar range. Further property-based optimization of aurones was performed, yielding a series of CK2 inhibitors with enhanced lipophilic efficiency. The most potent compound 12m (BFO13) has CLipE = 4.94 (CLogP = 3.5; IC50 = 3.6 nM) commensurable with the best known inhibitors of CK2.

Synthesis, antibacterial activity, and quantitative structure-activity relationships of new (Z)-2-(nitroimidazolylmethylene)-3(2 H)-benzofuranone derivatives

A new series of (Z)-2-(1-methyl-5-nitroimidazole-2-ylmethylene)-3(2 H)-benzofuranones (11a-p) and (Z)-2-(1-methyl-4-nitroimidazole-5-ylmethylene)-3(2 H)-benzofuranones (12a-m) were synthesized and assayed for their antibacterial activity against Gram-positive and Gram-negative bacteria. Most of the 5-nitroimidazole analogues (11a-p) showed a remarkable inhibition of a wide spectrum of Gram-positive bacteria (Staphylococcus aureus, Streptococcus epidermidis, MRSA, and Bacillus subtilis) and Gram-negative Klebsiella pneumoniae, whereas 4-nitroimidazole analogues (12a-m) were not effective against selected bacteria. The quantitative structure-activity relationship investigations were applied to find out the correlation between the experimentally evaluated activities with various parameters of the compounds studied. The QSAR models built in this work had reasonable predictive power and could be explained by the observed trends in activities.

Novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides useful as anthihyperglycemic agents

This invention relates to novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides, to the processes for their preparation, to methods for using the compounds, and to pharmaceutical compositions thereof. The compounds have pharmaceutical properties which render them beneficial for the treatment of diabetes mellitus and associated conditions.